Copertina

Autoimmune Complications of Lymphoproliferative Diseases

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Wilma Barcellini, Bruno Fattizzo
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Non‐Clonal Lymphoproliferative Diseases
di: Stefan Dirnhofer, et al.
Pubblicazione: (2025)

Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years
di: Terhi K. Friman, et al.
Pubblicazione: (2026)

Remote Monitoring of CAR T‐Cell Treated Patients by a Specialized Nurse to Detect and Manage Late Complications: Report of the CARAMA Program
di: Fanny Colin, et al.
Pubblicazione: (2025)

Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study
di: Francesco Versino, et al.
Pubblicazione: (2026)

Real World Incidence and Etiology of Infectious Complications in Adults With Ph‐Negative Acute Lymphoblastic Leukemia Treated With the Pediatric‐Inspired GIMEMA LAL1913 Program. A Campus All Study
di: Patrizia Zappasodi, et al.
Pubblicazione: (2025)

Clonal Hematopoiesis: Impact on Health and Disease
di: Francisco Caiado, et al.
Pubblicazione: (2025)

Clustering Based on Innate Immunity Reveals Differential Dysregulation Based on Disease Severity in Myelodysplastic Neoplasms
di: Pedro Robson Costa Passos, et al.
Pubblicazione: (2025)

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease
di: A. Bernardelli, et al.
Pubblicazione: (2026)

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
di: Jana Gregorova, et al.
Pubblicazione: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
di: Ganggang Wang, et al.
Pubblicazione: (2025)

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation
di: Francesco Autore, et al.
Pubblicazione: (2025)

Circulating Levels of PF4/CXCL4 in Patients With BCR: :ABL1 ‐Negative Myeloproliferative Neoplasms: A New Potential Prognostic Factor for Disease Progression
di: Valentina Bellani, et al.
Pubblicazione: (2025)

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda
di: C. Cattaneo, et al.
Pubblicazione: (2025)

522 | CLINICAL APPROACH AND OUTCOME OF DIFFUSE LARGE B CELL LYMPHOMA WITH PERSISTENT PET POSITIVITY AFTER FRONTLINE TREATMENT: SUBGROUP ANALYSIS OF THE STRIDER STUDY
di: M. Bisio, et al.
Pubblicazione: (2025)

342 | ANTI‐CD19 CHIMERIC ANTIGEN RECEPTOR T‐CELLS THERAPY IS EFFECTIVE IN SECONDARY CNS LYMPHOMA REFRACTORY TO HIGH‐DOSE METHOTREXATE‐BASED CHEMOTHERAPY
di: P. Angelillo, et al.
Pubblicazione: (2025)

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
di: Paola Guglielmelli, et al.
Pubblicazione: (2026)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
di: Juliette Penichoux, et al.
Pubblicazione: (2025)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
di: Tengfei Shi, et al.
Pubblicazione: (2025)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
di: Akihiko Izumi, et al.
Pubblicazione: (2025)

444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
di: V. Musteata, et al.
Pubblicazione: (2025)

72 | SEQUOIA 5‐YEAR FOLLOW‐UP IN ARM C: FRONTLINE ZANUBRUTINIB IN PATIENTS WITH DEL(17P) AND TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
di: C. S. Tam, et al.
Pubblicazione: (2025)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
di: Fuli Fan, et al.
Pubblicazione: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
di: Yutaka Shimazu, et al.
Pubblicazione: (2025)

598 | REDEFINING CLASSIFICATION ALGORITHM AND STAGING SYSTEM IN MARGINAL ZONE LYMPHOMA
di: C. Bommier, et al.
Pubblicazione: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
di: Dong Liang, et al.
Pubblicazione: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Pubblicazione: (2025)

397 | ROBUST SINGLE AGENT ACTIVITY OF BI‐1808, A TUMOR NECROSIS FACTOR RECEPTOR 2 BLOCKER/DEPLETER, IN T CELL LYMPHOMA PATIENTS
di: S. Barta, et al.
Pubblicazione: (2025)

12 | IMAGING BIOMARKERS FOR THE DEFINITION OF RESPONSE IN THE GHSG HD18, GHSG HD21 AND LYSA AHL2011 TRIALS FOR ADVANCED‐STAGE HODGKIN LYMPHOMA
di: J. Ferdinandus, et al.
Pubblicazione: (2025)

15 | EARLY PET RESPONSE PREDICTS RISK OF RELAPSE AFTER 2L AXI‐CEL IN LARGE B‐CELL LYMPHOMA
di: A. Kuhnl, et al.
Pubblicazione: (2025)

301 | SOCIOECONOMIC DISPARITIES, DISEASE BURDEN AND TREATMENT INTENSITY IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA TREATED AT AN URBAN ACADEMIC CANCER CENTER
di: H. J. Cherng, et al.
Pubblicazione: (2025)

300 | DIFFUSE LARGE B‐CELL LYMPHOMA IN BRAZIL: A COMPREHENSIVE ANALYSIS OF SOCIODEMOGRAPHIC PATTERNS
di: G. Duffles, et al.
Pubblicazione: (2025)

75 | POPULATION‐WIDE INTRODUCTION OF DOSE‐ADJUSTED EPOCH‐R IN HIGH‐GRADE B‐CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS WITH DLBCL MORPHOLOGY
di: W. Alduaij, et al.
Pubblicazione: (2025)

578 | PATTERNS OF CHEMOIMMUNOTHERAPY USE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE US COMMUNITY SETTING
di: J. Burke, et al.
Pubblicazione: (2025)

767 | AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL FAILURE REQUIRING HEMODIALYSIS. A SINGLE‐CENTER EXPERIENCE
di: I. Kliuchagina, et al.
Pubblicazione: (2025)

610 | RELATIVE EFFICACY OF VENETOCLAX PLUS IBRUTINIB VERSUS BRUTON TYROSINE KINASE INHIBITOR MONOTHERAPY AND CHEMOIMMUNOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
di: N. Ghosh, et al.
Pubblicazione: (2025)

861 | BRIDGING RADIATION THERAPY IN CAR‐T THERAPY
di: T. Li, et al.
Pubblicazione: (2025)

827 | WITHDRAWN
Pubblicazione: (2025)

826 | PET‐CT–ADAPTED TREATMENT FOR EARLY‐STAGE DIFFUSE LARGE B‐CELL LYMPHOMA WITHOUT RISK FACTORS: PRELIMINARY ANALYSIS FROM THE GATLA GROUP
di: A. Cerutti, et al.
Pubblicazione: (2025)

553 | DIGITAL TECHNOLOGY AND NATURAL LANGUAGE PROCESSING IN ACTION: EXPLORING THE BELGIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT POPULATION WITH THE BE‐CLLEAR STUDY
di: M. Vanderkerken, et al.
Pubblicazione: (2025)

837 | AXICABTAGENE CILOLEUCEL CAR T‐CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA
di: I. E. Karsten, et al.
Pubblicazione: (2025)